Academic, Phase I/II Trial on T Cells Expressing a Third-Generation GD2 Chimeric Antigen Receptor and Inducible Caspase-9 Safety Switch for Treatment of Relapsed/Refractory High-Risk Neuroblastoma

被引：0
|
作者：
Del Bufalo, F. [1 ]
Del Baldo, G. [1 ]
Mastronuzzi, A. [1 ]
Serra, A. [1 ]
De Ioris, M. A. [1 ]
Castellano, A. [1 ]
Caruana, I. [1 ]
Bertaina, V. [1 ]
Sinibaldi, M. [1 ]
Di Cecca, S. [1 ]
DeAngelis, B. [1 ]
Garganese, M. C. [2 ]
Merli, P. [1 ]
Pira, G. Li [1 ]
Pagliara, D. [1 ]
Leone, G. [3 ]
Quintarelli, C. [1 ]
Locatelli, F. [4 ]
机构：
[1] IRCCS Bambino Gesu Childrens Hosp, Pediat Haematol Oncol Cell & Gene Therapy & Haema, Rome, Italy
[2] IRCCS Bambino Gesu Childrens Hosp, Nucl Med Unit, Imaging Dept, Rome, Italy
[3] IRCCS Bambino Gesu Childrens Hosp, Transfus Unit, Rome, Italy
[4] Sapienza Univ Rome, IRCCS Bambino Gesu Childrens Hosp, Pediat Haematol Oncol Cell & Gene Therapy & Haem, Rome, Italy
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O0111
引用
收藏
页码：S53 / S54
页数：2
相关论文
共 15 条
  • [1] GENERATION AND ADMINISTRATION OF AUTOLOGOUS T CELLS TRANSDUCED WITH A 3RD GENERATION GD2 CHIMERIC ANTIGEN RECEPTOR FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA
    Louis, C. U.
    Savoldo, B.
    Heczey, A.
    Yvon, E.
    Gee, A.
    Rooney, C.
    Heslop, H.
    Dotti, G.
    Brenner, M. K.
    CYTOTHERAPY, 2014, 16 (04) : S19 - S20
  • [2] Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China
    Yang, Lihua
    Ma, Xiaoli
    Liu, Yu-Chen
    Zhao, Wen
    Yu, Lihua
    Qin, Maoquan
    Zhu, Guanghua
    Wang, Kai
    Shi, Xiaodong
    Zhang, Zhaoxia
    Wang, Jingfu
    Sun, Yuan
    Dong, Lujia
    Tsao, Shih-Ting
    Zhang, Rui
    Chang, Lung-Ji
    BLOOD, 2017, 130
  • [3] Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma
    Wu, Huantong
    Zhang, Guangji
    Liu, Zhongfeng
    Liu, Weihua
    Wang, Xuan
    Zhao, Yu
    CYTOTHERAPY, 2024, 26 (11) : 1308 - 1319
  • [4] International, Multicenter Phase II Trial With Humanized Anti-GD2 Monoclonal Antibody Naxitamab for Treatment of Refractory/Relapsed High-Risk Neuroblastoma: Efficacy and Safety Data
    Mora, J.
    Chan, G.
    Morgenstern, D.
    Nysom, K.
    Bear, M.
    Dalby, L. W.
    Lisby, S.
    Kushner, B.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S294 - S294
  • [5] A Cancer Research UK phase I trial of anti-GD2 chimeric antigen receptor (CAR) transduced T-cells (1RG-CART) in patients with relapsed or refractory neuroblastoma
    Straathof, Karin
    Flutter, Barry
    Wallace, Rebecca
    Thomas, Simon
    Cheung, Gordon
    Collura, Angela
    Gileadi, Talia
    Barton, Jack
    Wright, Gary
    Inglott, Sarah
    Edwards, David
    Barton, Claire
    Dyer, Karen
    Westwood, Nigel
    Loka, Thalia
    Depani, Sarita
    Howe, Karen
    Barone, Giuseppe
    Pule, Martin
    Anderson, John
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
    George, Philip
    Dasyam, Nathaniel
    Giunti, Giulia
    Mester, Brigitta
    Bauer, Evelyn
    Andrews, Bethany
    Perera, Travis
    Ostapowicz, Tess
    Frampton, Chris
    Li, Peng
    Ritchie, David
    Bollard, Catherine M.
    Hermans, Ian F.
    Weinkove, Robert
    BMJ OPEN, 2020, 10 (02):
  • [7] CARPETS: A Phase I study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma and refractory solid tumors
    Brown, Michael
    Gargett, Tessa
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children
    Del Bufalo, Francesca
    Quintarelli, Concetta
    De Angelis, Biagio
    Caruana, Ignazio
    Sinibaldi, Matilde
    Vinti, Luciana
    Merli, Pietro
    Algeri, Mattia
    Ruggeri, Annalisa
    Galaverna, Federica
    Cirillo, Valentina
    Cefalo, Maria Giuseppina
    Pira, Giuseppina Li
    Leone, Giovanna
    Bertaina, Valentina
    Fassio, Franca
    Gunetti, Monica
    Iacovelli, Stefano
    Locatelli, Franco
    BLOOD, 2019, 134
  • [9] Third Generation CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed or Refractory Chronic Lymphocytic Leukemia - Update of the Ongoing Academic Phase 1/2 Trial (HD-CAR-1)
    Derigs, P.
    Kunz, A.
    Dreger, P.
    Schmitt, A.
    Schubert, M. -L.
    Bruggemann, M.
    Bernhard, H.
    Kobbe, G.
    Lindemann, A.
    Rummel, M.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Korell, F.
    Laier, S.
    Ho, A. D.
    Muller-Tidow, C.
    Schmitt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 41 - 42
  • [10] Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
    Tang, Xiao-Yi
    Sun, Yao
    Zhang, Ang
    Hu, Guo-Liang
    Cao, Wei
    Wang, Dan-Hong
    Zhang, Bin
    Chen, Hu
    BMJ OPEN, 2016, 6 (12):
12